Core Viewpoint - The conference highlighted the optimistic outlook for Chinese assets, particularly in the technology sector, amidst a global trend of investment diversification and a consensus on the value of gold as a hedge [2][16]. Group 1: Market Performance and Economic Insights - The A-share market's strong performance is attributed to a decline in risk premiums rather than improvements in corporate earnings, indicating improved market expectations [4]. - The current bull market is believed to have entered its second phase, driven by fundamental improvements in technology sectors, with a focus on value sectors like real estate and consumer goods [7][9]. - The global economic outlook suggests a slowdown in GDP growth from 3.0% in 2025 to 2.8% in 2026, with inflation rates expected to remain stable, providing central banks with policy flexibility [12]. Group 2: Investment Strategies and Recommendations - Investment in Chinese assets is expected to increase, particularly in high-tech sectors such as AI, automation, and biotechnology, as global investors recognize the potential for growth [10][22]. - A diversified approach to global stock markets is recommended, with a preference for U.S. stocks due to their scale and quality, while being cautious of trade uncertainties that could impact market stability [19]. - The consensus among economists is to increase allocations in gold as a strategic asset, with expectations of at least a 5% price increase due to historical performance during rate cuts and geopolitical uncertainties [17][18]. Group 3: Regional Market Analysis - In the U.S. market, there is a preference for high-quality and cyclical stocks, while in Japan, companies benefiting from domestic inflation and governance reforms are favored [19][20]. - European markets face growth challenges, with a projected GDP growth of only 1% in 2025, suggesting a focus on resilient sectors like defense and banking [20]. - Emerging markets are viewed favorably for domestic-oriented companies and financial stocks, while exporters and semiconductor hardware firms are advised against [21].

天眼查App显示，近日，河北鑫煜农生物科技有限公司成立，法定代表人为韩秀喜，注册资本300万人 民币，经营范围为许可项目：饲料生产;农药零售;农药批发;检验检测服务（依法须经批准的项目，经相 关部门批准后方可开展经营活动，具体经营项目以批准文件或许可证件为准）一般项目：化肥销售;肥 料销售;农业机械服务;农林牧副渔业专业机械的安装、维修;农林牧渔机械配件销售;生物有机肥料研发; 土壤与肥料的复混加工;海洋生物活性物质提取、纯化、合成技术研发;复合微生物肥料研发;工程和技术 研究和试验发展;技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广;农产品的生产、销 售、加工、运输、贮藏及其他相关服务;农林牧渔业废弃物综合利用;农作物病虫害防治服务;林业专业及 辅助性活动;农业专业及辅助性活动;农作物栽培服务;农作物种子经营（仅限不再分装的包装种子）（除 依法须经批准的项目外，凭营业执照依法自主开展经营活动）。 ...

Core Insights - A total of 37 Chinese concept stocks have returned to the Hong Kong market through dual primary listings or secondary listings as of October 21, with 24 companies opting for dual primary listings and 13 for secondary listings [1][4] - The return of Chinese concept stocks is primarily driven by companies in the frontier technology sector, including smart driving, biotechnology, and advanced manufacturing [1][6] - The Hong Kong Stock Exchange (HKEX) offers significant advantages in terms of listing time, procedures, costs, and exemption conditions, which is expected to facilitate the continued return of Chinese concept stocks [1][6] Group 1 - Recent dual primary listings include smart driving companies WeRide and Pony.ai, which have both passed the HKEX hearing and are set to list [2] - The dual primary listing strategy is seen as crucial for smart driving companies to expand financing channels, enhance valuation stability, and connect with core markets [2] - Biotech companies are also planning dual primary listings, with Tianjing Biotechnology announcing its intention to conduct an IPO in Hong Kong [2] Group 2 - Hesai Technology became the first lidar company to achieve a dual primary listing, raising over 4.16 billion HKD, marking the largest IPO by a Chinese concept stock returning to Hong Kong in nearly four years [3] - The return of high-quality Chinese concept stocks to the Hong Kong market is supported by favorable policies and ongoing market reforms [4] - The HKEX has introduced mechanisms such as "same share, different rights" and relaxed listing requirements for unprofitable biotech firms, enhancing its capacity to accommodate Chinese concept stocks [4]

Core Insights - A total of 37 Chinese concept stocks have returned to the Hong Kong market through dual primary listings or secondary listings as of October 21, indicating a significant trend of quality Chinese companies returning to Hong Kong [1][4] - The technology sector, particularly in areas such as smart driving, biotechnology, and advanced manufacturing, has become a new driving force for the return of Chinese concept stocks to Hong Kong [1][5] - The Hong Kong Stock Exchange (HKEX) offers advantages in terms of listing time, procedures, costs, and exemption conditions, which are expected to facilitate the continued return of Chinese concept stocks [1][5] Group 1: Recent Listings - Smart driving companies, such as WeRide and Pony.ai, have recently passed the HKEX hearing, indicating their imminent dual primary listings on both NASDAQ and HKEX [2] - The dual primary listing is strategically significant for smart driving companies as it broadens financing channels and enhances valuation stability [2] Group 2: Market Trends - The return of quality Chinese concept stocks to the Hong Kong market is supported by favorable policies and ongoing reforms in the Hong Kong market [4][5] - The average daily trading volume in the Hong Kong market has increased by 132% year-on-year, reaching 2,483 billion HKD in the first eight months of this year, reflecting enhanced liquidity [5] Group 3: Policy Support - The China Securities Regulatory Commission (CSRC) has expressed support for quality Chinese concept stocks to return to the domestic and Hong Kong markets [4] - The Hong Kong government has also indicated its commitment to making Hong Kong the preferred return destination for Chinese concept stocks [4]

Group 1 - The Hong Kong pharmaceutical sector showed volatility, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index rising by 0.04%, the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increasing by 0.4%, the CSI 300 Pharmaceutical and Health Index up by 1.0%, the CSI Innovative Drug Industry Index climbing by 1.3%, and the CSI Biotechnology Theme Index gaining 1.4% [1] - The Hang Seng Innovative Drug ETF (159316) saw a net subscription of over 130 million units today, accumulating over 700 million yuan in inflows this month, ranking among the top in Hong Kong's innovative drug-related products [1] - Guotai Junan Securities believes that the recent surge in innovative drug business development (BD) transactions alleviates market concerns, maintaining the long-term industrial logic of Chinese innovative drugs going overseas, with expectations for continued active BD transactions as the year-end approaches [1] Group 2 - Multiple Chinese innovative drug data releases at the ESMO are generating high attention, with clinical data in areas such as PD-1 bispecific antibodies and ADCs reaching international leading levels, potentially boosting new overseas opportunities for innovative drugs [1]

Core Viewpoint - Foreign investors are optimistic about the asset allocation value of Chinese stocks, indicating a trend towards increasing investment in this market due to its current low allocation levels among global investors [2][4]. Group 1: Market Performance - On October 21, A-shares and Hong Kong stocks experienced a strong rally, with the Shanghai Composite Index rising by 1.36% to surpass 3900 points, and the ChiNext Index increasing by over 3% [2][8]. - The total trading volume in the Shanghai and Shenzhen markets reached 1.87 trillion yuan, an increase of 136.3 billion yuan compared to the previous trading day, with over 4600 stocks rising [8]. Group 2: Investment Strategies - Morgan Stanley recommends long-term investment in high-tech sectors in China, including artificial intelligence, automation, robotics, biotechnology, and high-end manufacturing, while also suggesting the allocation of high-quality dividend stocks to mitigate short-term market volatility [4]. - According to Guangfa Securities, increasing allocation to currently underweighted A-shares and H-shares is a key strategy for outperforming benchmarks like the MSCI Emerging Markets Index [5][6]. Group 3: Economic Outlook - The Federal Reserve's potential interest rate cuts are expected to improve liquidity in the Chinese stock market, historically leading to upward trends in A-shares and H-shares [5]. - Analysts predict that the narrowing of interest rate differentials between China and the U.S. and expectations of RMB appreciation will boost foreign capital inflows, supporting demand for A-shares and H-shares [6]. Group 4: Sector Analysis - The technology sector, particularly driven by AI trends, is expected to remain a market focus, with the TMT (Technology, Media, and Telecommunications) sector showing an upward trend in orders and inventory replenishment [9]. - Hong Kong's tech sector is anticipated to benefit from the current industrial trends, with foreign capital likely to return, further enhancing the market's performance [9].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 已向中國國家藥品監督管理局遞交瑞基奧侖賽在 （股份代號：2126） JW (Cayman) Therapeutics Co. Ltd 自願公告 藥明巨諾（開曼）有限公司* 研究及發展更新 （於開曼群島註冊成立的有限公司） 中國成人活動性系統性紅斑狼瘡患者中的I期研究數據 JW (Cayman) Therapeutics Co. Ltd （藥明巨諾（開曼）有限公司*）（「本公司」或「藥明 巨諾」，連同其附屬公司統稱「本集團」），一家獨立的、專注於研發、生產及商 業化細胞免疫治療產品的創新型生物科技公司，宣佈已向中國國家藥品監督 管理局（「NMPA」）遞交瑞基奧侖賽(relma-cel)在中國成人活動性系統性紅斑狼瘡 （「SLE」）患者中的I期研究數據，NMPA已接收數據，並受理會議申請。 瑞基奧侖賽在中國成人SLE患者中的安全性和療效數據更新 SLE是一種慢性自身免疫性疾病，可引起全身多臟器和組織受損。據 ...

Core Insights - The "Invest in Hainan, Win the Future" promotional event was held in Xiamen to attract businesses to invest in Hainan Free Trade Port [2] - The event coincided with the 10th anniversary of the Xiamen Hainan Chamber of Commerce, aiming to create a platform for efficient and precise business connections [2] Policy and Development - Experts from the Hainan Free Trade Port Talent Development Research Institute provided a systematic overview of the overall policy framework, key industry layout, and development plans [2] - Representatives from various cities and organizations in Hainan showcased regional industrial positioning and advantages, highlighting the unique industries in Hainan [2] Financial Support - The China Bank Hainan Branch offered professional interpretations of financial support policies for the Free Trade Port, providing dual guarantees of "policy + finance" for businesses [2] Networking and Collaboration - The event featured a bustling display and negotiation area where promotional materials were presented, facilitating in-depth one-on-one discussions between representatives and businesses [2] - Multiple cooperation intentions were reached during the event, indicating a vibrant negotiation atmosphere [2] Project Signings - The event resulted in the signing of five projects, including agreements between local governments and companies such as Linmo Cultural Industry Park and Hainan Liancheng Biotechnology Co., Ltd. [4] - Other signed agreements involved partnerships between the Yangpu Economic Development Zone and companies like Xinlai New Energy Co., Ltd. [4] Philanthropic Contributions - The Xiamen Hainan Chamber of Commerce made charitable donations of 200,000 yuan to Hainan Guoxing Middle School and 350,000 yuan to Hainan Normal University to support local education [4]

天眼查App显示，近日，郑州泓鸣生物科技有限公司成立，法定代表人为姚冠男，注册资本10万人民 币，经营范围为一般项目：生物有机肥料研发；生物基材料销售；化工产品销售（不含许可类化工产 品）；生物化工产品技术研发；化工产品生产（不含许可类化工产品）；专用化学产品销售（不含危险 化学品）；实验分析仪器销售；办公设备销售；饲料添加剂销售；技术服务、技术开发、技术咨询、技 术交流、技术转让、技术推广；非金属矿及制品销售；玻璃仪器销售；工程和技术研究和试验发展；仪 器仪表销售；塑料制品销售；办公设备耗材销售；日用品销售；通讯设备销售；电子产品销售；计算机 软硬件及辅助设备零售；饲料原料销售；肥料销售；复合微生物肥料研发（除依法须经批准的项目外， 凭营业执照依法自主开展经营活动）。 ...

10月20日，赛克赛斯生物科技股份有限公司在山东证监局办理辅导备案登记，拟首次公开发行股票并上 市，辅导券商为光大证券。 ...